

No data available
No data available
No data available
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Total Revenue | 16.06 | 5.20 | 3.07 |
| Total Expenses | 12.87 | 4.28 | 2.78 |
| Profit Before Tax | 3.18 | 0.91 | 0.29 |
| Profit After Tax | 2.61 | 0.82 | 0.28 |
| Operating Profit After Depreciation | 3.54 | 1.15 | 0.48 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Fixed Assets | 2.02 | 1.28 | 1.49 |
| Total Non Current Assets | 2.02 | 1.39 | 1.49 |
| Total Current Assets | 8.85 | 3.25 | 2.57 |
| Total Assets | 10.86 | 4.64 | 4.06 |
| Total Shareholder's Fund | 5.35 | 1.08 | 0.26 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Net Cash From Operating Activities | -2.21 | 0.23 | 0.68 |
| Net Cash Used In Investing Activities | -0.87 | -0.16 | -0.01 |
| Net Cash Used In Financing Activities | 2.98 | -0.04 | -0.63 |
No data available
No data available
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,794.30 | ₹4,30,512.67 |
| Divis Laboratories Ltd | ₹6,651.25 | ₹1,76,569.79 |
| Torrent Pharmaceuticals Ltd | ₹4,570 | ₹1,54,669.57 |
| Cipla Ltd | ₹1,383 | ₹1,11,725.01 |
| Zydus Lifesciences Ltd | ₹1,105.65 | ₹1,11,254.26 |
No data available
On 8 May 2026
02 May 2026, 04:24 pm
Accretion Nutraveda traded at Rs 194 on the BSE, a 50.39% premium to the issue price of Rs 129.
04 Feb 2026, 12:49 pm

Get started with us today and
start building your wealth journey
*By clicking, I agree to the T&C and Whatsapp updates.

Get started with us today and
start building your wealth journey
*By clicking, I agree to the T&C and Whatsapp updates.

Congratulations,
Your Digital savings bank account opening journey is complete.